Advert - Theramex - CASE/0270/08/24

• Date posted
  04 June 2025
• Sanction
  Advertisement,
• Case number/s
  CASE/0270/08/24 - Complainant v Theramex

For promoting Yselty (linzagolix) outside the terms of its marketing authorisation at a scientific congress dedicated to endometriosis, Theramex was ruled in breach of the following clauses of the 2021 Code:

Clause 2 - Bringing discredit upon, and reducing confidence in, the pharmaceutical industry

Clause 5.1 - Failing to maintain high standards

Clause 6.1 - Providing misleading information

Clause 11.2 - Promoting a medicine for an unlicensed indication